Molecular staging individualizing cancer management

Authors

Alex Mejia, Fellow, Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson UnviersityFollow
Stephanie Schulz, Assistant Professor, Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson UnviersityFollow
Terry Hyslop, Associate Professor and Director of the Division of Biostatistics, Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson UnviersityFollow
David S. Weinberg, Chair, Department of Medicine, Fox Chase Cancer CenterFollow
Scott A. Waldman, Chair, Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson UnviersityFollow

Document Type

Article

Publication Date

4-1-2012

Comments

This article has been peer reviewed. It is the authors' final version prior to publication in the Journal of Surgical Oncology. 2012, 105(5): 468-74. The published version is available at DOI: 10.1002/jso.21858. Copyright © John Wiley & Sons, Inc.

Abstract

Although the most important prognostic and predictive marker in colorectal cancer is tumor cells in lymph nodes, ∼30% of patients who are node-negative die from occult metastases. Molecular staging employing specific markers and sensitive detection technologies has emerged as a powerful platform to assess prognosis in node-negative colon cancer. Integrating molecular staging into algorithms that individualize patient management will require validation and the definition of relationships between occult tumor cells, prognosis, and responses to chemotherapy. J. Surg. Oncol. 2012; 105:468-474. © 2012 Wiley Periodicals, Inc.

Copyright © 2012 Wiley Periodicals, Inc.

Recommended Citation

Mejia, Alex; Schulz, Stephanie; Hyslop, Terry; Weinberg, David S.; and Waldman, Scott A., "Molecular staging individualizing cancer management" (2012). Department of Pharmacology and Experimental Therapeutics Faculty Papers. Paper 34.
https://jdc.jefferson.edu/petfp/34